Pearl Therapeutics was awarded the 2013 Drug Delivery Partnerships (DDP) Innovation Award for its co-suspension formulation technology, according to the company. The company is developing several metered dose inhalation products using the technology.
President and CEO Chuck Bramlage said, “We truly appreciate this award by our peers in the drug delivery industry. It highlights the innovation and operational excellence achieved by the entire Pearl team.”
Pearl Chief Medical Officer and Executive VP of Clinical development and medical affairs Colin Reisner commented, “In our view, Pearl’s co-suspension formulation technology has accelerated the clinical development of pulmonary medicines, allowing Pearl to move swiftly from study to study with confidence in the performance of the product over a broad range of doses, including sub-microgram doses. The co-suspension technology has enabled highly uniform and efficient formulations of potent inhaled medicines, dual and triple drug combination products without any in vitro drug-drug interaction, and stable delivery under a variety of conditions. Importantly, we have accomplished this using the simple metered-dose inhaler, obviating the need to test complex devices in patients who typically receive multiple therapies at once.”
The company says that it plans to begin a Phase 3 program with two efficacy studies of a single dose of its PT003 compared to PT001, PT005, tiotropium and placebo by mid-2013. PT003 is a fixed dose combination MDI for the treatment of COPD that contains glycopyrrolate (GP) and formoterol fumarate (FF). The company raised $65 million for the Phase 3 program last year.
Read the Pearl press release.
